Azitra Inc. AZTR 深 沪
已收盘 02-06 16:00:00 美东时间
0.208
-0.001
-0.72%
华盛通- 最 高0.22
- 今 开0.206
- 成交量 150.31万股
- 最 低 0.205
- 昨 收 0.2095
- 总市值 223.41万
- 52周最高 2.9704
- 市盈率 静 --
- 换手率 13.99%
- 52周最低 0.2016
- 委 比 0.00%
- 总股本 1074.07万
- 历史最高 1034.964
- 量 比 0.88
- 振 幅 7.16%
- 历史最低 0.2016
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatol...
02-07 05:15
Azitra Receives NYSE American Approval Of Compliance Plan, Must Regain Listing Standards By April 1, 2027
Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the
2025-12-18 05:11
Pharma Company Azitra Shoots Down "False Report" of a $44M Stock Offering
Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has come to the Company's attention that a report
2025-11-07 19:06
Azitra, Inc. Addresses False Report Regarding Sale of Securities
BRANFORD, Conn., Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatol...
2025-11-07 19:00
Azitra To Present Preclinical Progress For ATR-01 Program, Targeting Treatment Of Ichthyosis Vulgaris At BIO-Europe Conference
ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgarisPreclinical data show production of active, functional filaggrin delivered through human stratum
2025-10-20 20:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) stock increased by 95.3% to $8.79 during...
2025-10-20 20:08
Azitra Inc Faces NYSE Compliance Deadline Notice
Azitra Inc ( ($AZTR) ) has provided an update. On October 1, 2025, Azitra, Inc....
2025-10-04 05:17
Azitra Receives Notice of Non-Compliance from NYSE American
BRANFORD, Conn., Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatol...
2025-10-04 04:45
Azitra Stock (AZTR) Rockets on Clinical Trial Update
Azitra stock rallied on Wednesday alongside a clinical trial update.
2025-08-27 21:25
Azitra Doses First Patient In Phase 1/2 Trial Of ATR04-484 For EGFRi-Associated Rash
Azitra, Inc. ("Azitra") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the dosing of the first patient in its Phase 1/2
2025-08-27 20:11
